Key takeaways:

• Retatrutide, a triple-hormone agonist, was associated with 24.2% weight loss at the highest dose for people with obesity.
• The GLP-1/GIP/glucagon agonist also reduced HbA1c and body weight in type 2 diabetes.
  
  https://www.healio.com/news/endocrinology/20230626/this-raises-the-bar-phase-2-data-show-24-weight-loss-with-tripleagonist-retatrutide